Micro-x Ltd. · ASX:MX1
Micro-x — Shareholder Meeting (November 2025)
18 slides from Micro-x's shareholder meeting presentation, Nov 11, 2025
Slide 1: 2025 Annual General Meeting CEO Presentation
For personal use only 2025 ANNUAL GENERAL MEETING CEO Presentation Ki n gsl ey Hal l Chi e f Ex e cuti ve Of f i ce r 11 No vem be r 2 02 5
Slide 2: Important Notice
IMPORTANT NOTICE SCOPE & LI MITATION S T his Pre se nt a t io n ha s be en pre pa re d by M ic ro -X L im i t ed ( M i cro -X or t he C om pa ny) (A SX .M X1). T he Pre s e nta t i on i s a s um ma ry onl y a nd d oe s not co nt a in a l l t he i nform at io n ab out t he Co mpany ’s as se t s and l
Slide 3: Creating Revolutionary X-ray Imaging to Better Lives
For personal use only CREATING REVOLUTIONARY X -RAY IMAGING TO BETTER LIVES Cu rio us I Co lla borat iv e I Determined Micro-X Annual General Meeting 2025 3
Slide 4: Overview: Growing commercial momentum
OVERVIEW Growing commercial momentum ABOUT MICRO-X PURPOSE • An Australian technology company commercialising For personal use only Creating revolutionary X-ray imaging to better lives innovative X-ray and CT imaging solutions for global healthcare and security markets • 87 staff across – Australia,
Slide 5: NEX Technology Platform
NEX TECHNOLOGY PLATFORM Proprietary and customisable platform for use across multiple applications Nano Electronic X-ray (NEX) technology platform has evolved from our first generation NEX tube for mobile medical X-ray to multiple tube CT imaging. For personal use only Our high voltage generator and
Slide 6: Medical Imaging Portfolio
MEDICAL IMAGING PORTFOLIO Pioneering smaller, smarter X-ray and CT through patented technology platform ROVER PLUS HEAD CT FULL BODY CT - MOBI LE DIGITAL RADIOGRAPHY - MOBI LE STRO KE DETE CTIO N - PORTABLE IMAGING SOLUTION For personal use only Ultra-mobile X-ray systems delivering high Light, port
Slide 7: Strategies & Priorities
STRATEGIES & PRIORITIES Three key near-term objectives with a focus on tangible outcomes 01 02 03 For personal use only Build Rover Sales Commence Head CT Monetise Imaging Trials Security Division Focus on building durable growth and larger Trials providing pathway to regulatory Execute ongoing part
Slide 8: Recent Achievements
RECENT ACHIEVEMENTS Growing commercial momentum positioning us for a strong 2026 FY2025 FY2026 YTD For personal use only $25M to fund Full Body CT $5.6M Security Partnership $3.3M Rover Plus order World first 3D CT images DHS Contract – up to $31.7M Major U.S. Supply Agreement Gold award for Head CT
Slide 9: Expanded Partnerships
EXPANDED PARTNERSHIPS Non-dilutive funding de-risks our technology development and unlocks value For personal use only Up to $31.7M funding Up to $25M funding $8M funding $4.4M funding Development Checkpoints & Baggage Full Body CT Head CT Head CT Partners Scanner – U.S. Airports – Portable & lightw
Slide 10: Rover - Proven Technology
ROVER - PROVEN TECHNOLOGY Delivering on direct sales focus and securing larger contracts $3.3M order for Malaysian Ministry of Health - largest single order in Micro-X history • Order following successful tender win by Malaysian distributor Integrated Medical Systems • Delivery underway - to be comp
Slide 11: Head CT – In Advanced Development
HEAD CT – IN ADVANCED DEVELOPMENT Hospital and ambulance imaging trials to inform regulatory applications and demonstrate roadworthiness Major technical milestone achieved - commencing human imaging trials • First of three test benches completed and ready for ASA imaging trial, pending regulatory li
Slide 12: Monetising Our Security Business
MONETISING OUR SECURITY BUSINESS Expanding fully funded development with US DHS and Billion Prima Up to $31.7M contracted development with DHS - latest contract extension of up to $2.5M • Extension to advance detection algorithms for Self-Screening Passenger Checkpoint • TSA testing ongoing for Chec
Slide 13: Full Body CT
FULL BODY CT Bringing full diagnostic CT scanning to the patient $25M development funding contract with US Govt biomedical research agency ARPA-H • Initial funding of $12.5M for first 2 years - up to $25M for a total of 5 years • Contract to design and deliver a lightweight and portable CT scanner f
Slide 14: 2026 and Beyond
For personal use only 2026 AND BEYOND Micro-X Annual General Meeting 2025 14
Slide 15: Milestones for 2026
MILESTONES FOR 2026 COM MERCIAL DEV ELOPMENT PARTNERSHIPS For personal use only Mobile DR Head CT Full Body CT Security Sales growth - current & new markets Undertake hospital imaging trials Develop Full Body test bench Execute security partnerships to unlock value Launch 2026 Rover model update Com
Slide 16: Commercial Timeline
COMMERCIAL TIMELINE Bringing a portfolio of medical and security products to market Products Funding / Status 2025 2026 2027 For personal use only Approved and in Revenue Execute larger sales Cashflow positive Further growth opportunities operations 400+ units sold to date Hospital human Regulatory
Slide 17: Corporate & Financials
CORPORATE Institutional /Strategic 42.5% & FINANCIALS Retail and HNW 55.2% Board & Management 2.3% For personal use only FINANCIALS & SHAREHOLDERS SHARE CAPITAL (10 November 2025) $18.3m Contracted Payments FY26 onwards Cash ~$2.0m (30 Sept 2025) Share price $0.098 per share Revenue $13.1m (FY2025)
Slide 18: Wrap Up
WRAP UP A clear path forward 1 For personal use only Commercial & customer focus is delivering results 2 Rover Plus sales momentum – building towards breakeven 3 Stroke imaging about to commence trials 4 Near term opportunity to monetise security business 5 Validated by strong partners – funding & a